World Health Organization

20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT

Prequalification Unit Inspection services
WHO PUBLIC INSPECTION REPORT
DESK ASSESSMENT OF CONTRACT RESEARCH ORGANIZATION (CRO)
WHOPIR

Part 1	**General information**	
Company information		
Name of Company	Anapharm Europe, S.L.U (Brand name as Anapharm Bioanalytics)	
Corporate address of Company	2nd floor Encuny, 22 08038, Barcelona Spain	
Inspected sites		
Name & address of sites where the studies in the scope of this desk review assessment took place	As above	
Desk assessment details		
Date of review	25 September 2020	
Product and study information covered by this desk assessment	Analytical study code: 11ANE-1902 Levonorgestrel 1.5 mg	
Part 2	**Summary of SRA/NRA inspection evidence considered (from most recent)**	
US FDA, USA	Dates of inspection:	3-7 June 2019
	Type of inspection:	FY2019 analytical BIMO program inspection
	Unit:	Bioanalytical unit
	Type of study covered:	Bioequivalence studies
Part 3	**Summary of the last WHO inspection**	
Date and conclusion of most recent WHO inspection	The site has not been previously inspected by WHO.	
Brief description of the site's activities	Anapharm Bioanalytics offers high performance liquid chromatography mass spectrometry (LC-MS/MS) and Ligand Binding Assays (LBA) bioanalytical services to pharmaceutical industry throughout all stages of drug development.	

	The organization has been authorized/licensed to carry out the following activities: - Analysis and research laboratory - Drug determination of small and large molecules in biological fluids and matrices - Analytical part of preclinical, Phase I-III and Bioavailability / Bioequivalence studies - PK, ADA, Cell-based Assays and biomarker testing.
Abbreviations	**Meaning**
CCs	Calibration Curve standards
CAPA	Corrective and preventive action
CROMF	CRO master file
GCP	Good clinical practices
GLP	Good laboratory practices
NC	Non-conformity
NRA	National regulatory agency
QA	Quality assurance
QC	Quality control
SOP	Standard operating procedure
SRA	Stringent regulatory authority

Part 4	**Summary of the assessment of supporting documentation**

a) Clinical trial license granted by the local authority:

As Anapharm Bioanalytics only performed the bioanalytical analysis of the study, a clinical trial license for this is not applicable.

b) CRO Master File:

A CRO Master File was authorized on 18 Sep 2020. The Site Master File was arranged in accordance with WHO Technical Report Series, No. 957, 2010 Annex 7 for Guidelines for the preparation of a contract research organization master file.

c) List of all regulatory inspections performed in the last 3 years and their outcome:

Ministry of Health in Catalonia is responsible for GLP inspection of facilities located within this territory and is also responsible for issuing the GLP compliance certificates. The GLP certificates are issued by the General Directorate of Ordering and Regulation of Health Resources (Direcció General d'Ordenació Professional i Regulació Sanitària) and inspections are performed by members of the Sub-directorate General for Healthcare and Pharmaceutical Planning and Quality (Subdirecció General d'Ordenació i Qualitat Sanitàries I Farmacèutiques). The GLP compliance certificate issued by the catalan authority is recognized and adopted by the Spanish state and by the European Comission.

A GLP inspection was planned for April 2020. However, due to the exceptional situation caused by the COVID-19, it was postponed until October 2020. Therefore, the GLP Certificate was extended and a copy of certificate was submitted.

Regarding the ANVISA inspection, since no report was received, and no observations were found, a CAPA plan was not applicable. The certification published on Brazil Official Gazette was available.

For more details, refer to Part 2 of this report.

d) Copy of any warning letter, or equivalent regulatory action, issued by any authority for the site:

There are no warning letters issued.

e) Confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the studies conducted for WHO product(s) has been performed and all matters dealt with:

A Quality assurance statement, stating that the study of Levonorgestrel mentioned in the statement letter was subjected to periodical internal audits by the QA-Unit of Anapharma Europe, S.L.U. The statement was signed by the QA-Unit Director on 10 Feb 2012.

f) IRB/IEC clinical trial approval (including the approved protocol, the amended protocol and consent form):

As a bioanalytical laboratory, the organization does not perform the clinical part of the studies. Therefore, Ethics Committee's approval is not applicable.

g) A list of any study failures in the last three years:

The laboratory is only involved in the sample analysis, but not in the statistic evaluations. Consequently, the detailed information about the conclusion of the BE studies would not be shared with the laboratory.

h) Additional documents submitted:

Not applicable.

Part 5	**Conclusion – Desk assessment outcome**

Based on the GCP/GLP/BE evidence received and reviewed, it is considered that a desk assessment is acceptable in lieu of a WHO onsite inspection. The site ***Anapharm Europe, S.L.U.*** located at ***Encuny, 22, 2nd floor, 08038 Barcelona; Spain*** is considered to have performed the study submitted to WHO PQT under an acceptable level of compliance with WHO guidelines.

This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.

Part 6	List of guidelines referenced in this inspection report

1. Guidance for organizations performing in vivo bioequivalence studies. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 9.
   Short name: WHO BE guidance or ***TRS996 Annex 9***
   http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex09.pdf

2. Good clinical laboratory practice (GCLP), WHO on behalf of the Special Programme for Research and Training in Tropical Diseases. Geneva, 2009
   Short name: WHO GCLP
   https://www.who.int/tdr/publications/documents/gclp-web.pdf

3. Guidelines for good clinical practice for trials on pharmaceutical products. WHO Technical Report Series, No. 850, 1995 (pp. 97–137). ***Short name: WHO GCP***
   http://apps.who.int/medicinedocs/en/d/Js5516e/19.11.html

4. Handbook – Good Laboratory Practice (GLP): quality practices for regulated non-clinical research and development – Annex I: The OECD Principles on GLP, 2nd ed., 2009. ***Short name: OECD GLP***
   http://www.who.int/tdr/publications/documents/glp-handbook.pdf

5. Standards and operational guidance for ethics review of health-related research with human participants. Guidance Document. Geneva, World Health Organization, 2011. ***Short name: WHO Ethics Committee Guidance***
   https://www.who.int/ethics/publications/9789241502948/en/

6. Model guidance for the storage and transport of time-and temperature-sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report. Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 9. ***Short name: WHO storage and transport guidance*** or ***TRS 961 Annex 9***
   http://apps.who.int/medicinedocs/documents/s18683en/s18683en.pdf

7. Guidelines for the preparation of a contract research organization master file, WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 7.
   Short name: WHO CROMF Guidelines or ***TRS No. 957, Annex 7***
   http://www.who.int/medicines/publications/44threport/en/

8. Glove use information leaflet, Patient Safety, Save lives clean your hands. Geneva, World Health Organization, 2009 (revised). ***Short name: Glove use information leaflet***
   http://www.who.int/gpsc/5may/Glove_Use_Information_Leaflet.pdf

9. WHO guidance on good data and record management practices. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 5.
Short name: TRS 996 Annex 5 or ***WHO GDRMP guidance***
http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex05.pdf

10. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Republication of multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Technical Report Series No. 992, Annex 7 with a new appendix 2. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-first Report Geneva, World Health Organization, 2017 (WHO Technical Report Series, No. 1003), Annex 6. ***Short name: TRS 1003 Annex 6***
http://apps.who.int/medicinedocs/documents/s23245en/s23245en.pdf

11. Good chromatography practice. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 4.
Short name: WHO TRS No. 1025, Annex 4
https://www.who.int/publications-detail/978-92-4-000182-4

12. WHO guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report. Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 9.
Short name: WHO TRS 1010, Annex 9
https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS1010annex9.pdf?ua=1